Theravance Biopharma, Inc. (NASDAQ:TBPH – Get Free Report) SVP Richard A. Graham sold 2,482 shares of Theravance Biopharma stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $10.22, for a total transaction of $25,366.04. Following the sale, the senior vice president now directly owns 346,839 shares in the company, valued at $3,544,694.58. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Theravance Biopharma Price Performance
NASDAQ:TBPH opened at $10.45 on Friday. The firm’s 50 day simple moving average is $9.39 and its 200 day simple moving average is $9.99. Theravance Biopharma, Inc. has a one year low of $8.25 and a one year high of $12.03. The company has a market cap of $520.41 million, a PE ratio of -11.00 and a beta of 0.33.
Institutional Investors Weigh In On Theravance Biopharma
Several hedge funds have recently added to or reduced their stakes in TBPH. Principal Financial Group Inc. acquired a new stake in Theravance Biopharma during the 1st quarter worth approximately $101,000. Acadian Asset Management LLC boosted its position in Theravance Biopharma by 51.6% during the 1st quarter. Acadian Asset Management LLC now owns 8,277 shares of the biopharmaceutical company’s stock worth $77,000 after buying an additional 2,818 shares during the period. Vanguard Group Inc. boosted its position in Theravance Biopharma by 10.3% during the 1st quarter. Vanguard Group Inc. now owns 6,947,947 shares of the biopharmaceutical company’s stock worth $66,421,000 after buying an additional 648,124 shares during the period. Charles Schwab Investment Management Inc. boosted its position in Theravance Biopharma by 3.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 402,640 shares of the biopharmaceutical company’s stock worth $3,850,000 after buying an additional 12,095 shares during the period. Finally, UBS Group AG boosted its position in Theravance Biopharma by 45.0% during the 1st quarter. UBS Group AG now owns 3,549 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 1,101 shares during the period. 99.10% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
About Theravance Biopharma
Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.
- Five stocks we like better than Theravance Biopharma
- Crypto vs Stocks: How to Choose Your Investments
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- What is a Low P/E Ratio and What Does it Tell Investors?
- MarketBeat Week in Review – 11/13 – 11/17
- How to Start Investing in Real Estate
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.